The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update
- PMID: 14623619
- DOI: 10.7326/0003-4819-139-10-200311180-00009
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update
Erratum in
- Ann Intern Med. 2004 Jan 20;140(2):151
Abstract
Background: The incidence of hepatocellular carcinoma was reported to be increasing in the United States. However, alternate explanations were diagnostic or reclassification bias and changes in the demographic features of the general population.
Objective: To examine the temporal trends in the incidence of hepatocellular carcinoma.
Design: Retrospective cohort study.
Setting: Information collected by population-based registries of the Surveillance, Epidemiology, and End Results (SEER) program.
Patients: Persons given a diagnosis of hepatocellular carcinoma between 1975 and 1998.
Measurements: Linear Poisson multivariate regression model, controlling for differences in age, sex, race or ethnicity, and geographic region among patients with hepatocellular carcinoma and in the underlying population.
Results: The overall age-adjusted incidence rates of hepatocellular carcinoma increased from 1.4 per 100 000 in 1975 to 1977 to 3.0 per 100 000 in 1996 to 1998. There was a 25% increase during the last 3 years of the study compared with the preceding 3 years (1993 to 1995). The increase affected most age groups above 40 years, with the greatest increase in the 45- to 49-year-old age group. White men had the greatest increase (31%) in the last time period (1996 to 1998) compared with 1993 to 1995. The Poisson regression model confirmed an almost 2-fold increase in the incidence rate ratio for hepatocellular carcinoma between 1975 to 1978 and 1996 to 1998.
Conclusions: The incidence of hepatocellular carcinoma continues to increase rapidly in the United States, with rates increasing the fastest in white men 45 to 54 years of age. These findings are consistent with a true increase and could be explained by consequences of hepatitis C virus acquired during the 1960s and 1970s.
Comment in
-
Prevention of hepatocellular carcinoma.Ann Intern Med. 2004 Jul 6;141(1):77; author reply 77-8. doi: 10.7326/0003-4819-141-1-200407060-00025. Ann Intern Med. 2004. PMID: 15238378 No abstract available.
Summary for patients in
-
Summaries for patients. Increasing rates of primary liver cancer in the United States.Ann Intern Med. 2003 Nov 18;139(10):I28. doi: 10.7326/0003-4819-139-10-200311180-00004. Ann Intern Med. 2003. PMID: 14623640 No abstract available.
Similar articles
-
Summaries for patients. Increasing rates of primary liver cancer in the United States.Ann Intern Med. 2003 Nov 18;139(10):I28. doi: 10.7326/0003-4819-139-10-200311180-00004. Ann Intern Med. 2003. PMID: 14623640 No abstract available.
-
Geographic variation within the United States in the incidence of hepatocellular carcinoma.J Clin Epidemiol. 2003 May;56(5):487-93. doi: 10.1016/s0895-4356(02)00605-4. J Clin Epidemiol. 2003. PMID: 12812824
-
Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study.Gastroenterology. 2004 Nov;127(5):1372-80. doi: 10.1053/j.gastro.2004.07.020. Gastroenterology. 2004. PMID: 15521006
-
Epidemiology of hepatocellular carcinoma.Clin Liver Dis. 2005 May;9(2):191-211, v. doi: 10.1016/j.cld.2004.12.009. Clin Liver Dis. 2005. PMID: 15831268 Review.
-
Hepatocellular carcinoma and hepatitis C in the United States.Hepatology. 2002 Nov;36(5 Suppl 1):S74-83. doi: 10.1053/jhep.2002.36807. Hepatology. 2002. PMID: 12407579 Review.
Cited by
-
Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma.Onco Targets Ther. 2013 Apr 22;6:577-83. doi: 10.2147/OTT.S44215. Print 2013. Onco Targets Ther. 2013. PMID: 23723713 Free PMC article.
-
Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.Liver Cancer. 2015 Mar;4(2):115-25. doi: 10.1159/000367734. Liver Cancer. 2015. PMID: 26020033 Free PMC article.
-
Interventional therapies for hepatocellular carcinoma.Cancer Imaging. 2012 Apr 5;12(1):79-88. doi: 10.1102/1470-7330.2012.0011. Cancer Imaging. 2012. PMID: 22487698 Free PMC article. Review.
-
Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States.J Clin Gastroenterol. 2012 Jan;46(1):71-7. doi: 10.1097/MCG.0b013e318224d669. J Clin Gastroenterol. 2012. PMID: 22157221 Free PMC article.
-
A radiomics-based model on non-contrast CT for predicting cirrhosis: make the most of image data.Biomark Res. 2020 Sep 17;8:47. doi: 10.1186/s40364-020-00219-y. eCollection 2020. Biomark Res. 2020. PMID: 32963787 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical